Clinical Trial Update: RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial of RN1201 Injection in newly diagnosed high-risk cytogenetic multiple myeloma patients who are ineligible or unwilling to undergo autologous stem …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• RN1201 Injection (RN1201)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT, Newly Diagnosed Multiple Myeloma (NDMM) | Phase 1 | Status: NOT_YET_RECRUITING